GSK Pharma Q2 Review— Temporary Hiccups Lead To Muted Show On A YoY Basis; Motilal Oswal Maintains Neutral

GSK Pharma's EBITDA margin expanded 250bp YoY to 34.3% (our est: 31.4%) due to steady other expenses costs and a cut in employee costs on a YoY basi

(Photo: GSK Pharma website). In addition to vaccines, GSK Pharma is building a specialty portfolio in the respiratory and oncology segments. Products launched in the oncology segment have also been well-received by healthcare professionals.

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In